CRISPR breakthrough could make CAR-T cancer therapy faster, cheaper, and more accessible

CAR-T cell therapy has been a game-changer for blood cancers, but its sky-high costs and complex manufacturing process put it out of reach for many patients. The standard approach requires extracting a patient's immune cells, shipping them to a specialized facility for genetic modification, and infusing them back — a process that takes weeks and can cost up to half a million dollars. Now, UC San Francisco researchers may have found a way to skip all of that.

The team developed a two-particle delivery system that sends CRISPR gene-editing tools and cancer-targeting DNA directly into T cells inside the body. The new DNA is inserted at a precise genomic location — an approach that outperformed traditional virus-based methods. In mice, a single injection wiped out nearly all detectable leukemia within two weeks, and the strategy also worked against multiple myeloma and a solid sarcoma tumor. Notably, the in vivo-engineered T cells also appeared to retain more "stemness" and proliferative capacity than their lab-made counterparts.

By the Numbers

• CAR-T therapies currently cost $400,000–$500,000 per patient
• In mice, leukemia was eliminated in nearly all animals within 2 weeks
• Engineered CAR-T cells made up as much as 40% of immune cells in some organs
• 7 CAR-T therapies are currently FDA-approved for blood cancers

Why it matters: If this approach translates to humans, it could eliminate the need for specialized manufacturing facilities, reduce costs dramatically, and allow community hospitals — not just major cancer centers — to offer CAR-T therapy. The team has founded Azalea Therapeutics to advance the platform toward clinical trials.